313 related articles for article (PubMed ID: 21232654)
1. Myelomagenesis: capturing early microenvironment changes.
Korde N; Maric I
Semin Hematol; 2011 Jan; 48(1):13-21. PubMed ID: 21232654
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; Rajkumar SV
Curr Hematol Malig Rep; 2010 Apr; 5(2):62-9. PubMed ID: 20425398
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
4. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
[TBL] [Abstract][Full Text] [Related]
5. Plasma cell neoplasms and related entities-evolution in diagnosis and classification.
Fend F; Dogan A; Cook JR
Virchows Arch; 2023 Jan; 482(1):163-177. PubMed ID: 36414803
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
7. Multiple myeloma and multiple plasmacytomas associated with free gamma heavy chain, free kappa light chain and IgGk paraproteins: an unusual triple gammopathy.
Deighan WI; O'Kane MJ; McNicholl FP; Keren DF
Ann Clin Biochem; 2016 Nov; 53(6):706-711. PubMed ID: 27166317
[TBL] [Abstract][Full Text] [Related]
8. The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?
Sidiqi MH; Aljama M; Kumar SK; Jevremovic D; Buadi FK; Warsame R; Lacy MQ; Dingli D; Gonsalves WI; Fonder AL; Hobbs MA; Hwa YL; Kapoor P; Kourelis T; Leung N; Muchtar E; Lust JA; Kyle RA; Go RS; Rajkumar VS; Gertz MA; Dispenzieri A
Blood Cancer J; 2020 May; 10(5):52. PubMed ID: 32376870
[TBL] [Abstract][Full Text] [Related]
9. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
[TBL] [Abstract][Full Text] [Related]
10. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Kyle RA; Rajkumar SV
Oncology (Williston Park); 2011 Jun; 25(7):578-86. PubMed ID: 21888255
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
Hillengass J; Moehler T; Hundemer M
Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
[TBL] [Abstract][Full Text] [Related]
12. Development of early treatment strategies for high-risk myeloma precursor disease in the future.
Landgren O; Rajkumar SV
Semin Hematol; 2011 Jan; 48(1):66-72. PubMed ID: 21232660
[TBL] [Abstract][Full Text] [Related]
13. Molecular imaging in myeloma precursor disease.
Mena E; Choyke P; Tan E; Landgren O; Kurdziel K
Semin Hematol; 2011 Jan; 48(1):22-31. PubMed ID: 21232655
[TBL] [Abstract][Full Text] [Related]
14. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
Golombick T; Diamond TH; Manoharan A; Ramakrishna R
Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182
[TBL] [Abstract][Full Text] [Related]
15. Stromal alterations in patients with monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma.
Bogun L; Koch A; Scherer B; Fenk R; Maus U; Bormann F; Köhrer K; Petzsch P; Wachtmeister T; Zukovs R; Dietrich S; Haas R; Schroeder T; Jäger P; Geyh S
Blood Adv; 2024 May; 8(10):2575-2588. PubMed ID: 38241490
[TBL] [Abstract][Full Text] [Related]
16. MGUS to myeloma: a mysterious gammopathy of underexplored significance.
Dhodapkar MV
Blood; 2016 Dec; 128(23):2599-2606. PubMed ID: 27737890
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
18. Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.
Pisano M; Cheng Y; Sun F; Dhakal B; D'Souza A; Chhabra S; Knight JM; Rao S; Zhan F; Hari P; Janz S
Front Immunol; 2021; 12():667054. PubMed ID: 34149703
[TBL] [Abstract][Full Text] [Related]
19. Multiple myeloma: clinical features and indications for therapy.
Dispenzieri A; Kyle RA
Best Pract Res Clin Haematol; 2005; 18(4):553-68. PubMed ID: 16026737
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
